| |
| |
|
| Insider
Information: |
Hooper Anthony C |
| Relationship: |
Director |
| City: |
Princeton |
| State: |
NJ |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
618,962 |
|
|
Indirect Shares
|
5,248 |
|
|
| Direct
Value |
$79,238,782 |
|
|
|
Indirect Value
|
$216,428 |
|
|
| Total
Shares |
624,210 |
|
|
| Total
Value |
$79,455,210 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
0
|
|
Stock
price went up :
|
1
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
1.0
|
0.0
|
| Percentage
Gain/Loss : |
 58.4%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Bristol-Myers Squibb Co |
BMY |
SVP ComOps Pres USJap ... |
2011-05-13 |
203,170 |
2011-05-13 |
5,248 |
Premium* |
|
|
Amgen Inc |
AMGN |
EVP, Global Commercial... |
2018-05-03 |
215,147 |
2011-10-27 |
0 |
Premium* |
|
|
MannKind Corp |
MNKD |
Director |
2024-02-04 |
176,153 |
|
0 |
Premium* |
|
|
Beigene Ltd |
BGNE |
Director |
2022-06-22 |
24,492 |
2021-06-16 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
93 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| AMGN |
Amgen Inc |
EVP, Global Commercial Ops. |
• • – |
2016-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
5,116 |
189,312 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Global Commercial Ops. |
• • – |
2013-03-02 |
4 |
D |
$92.58 |
$647,875 |
D/D |
(6,998) |
67,823 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Global Commercial Ops. |
• • – |
2013-01-28 |
4 |
A |
$0.00 |
$0 |
D/D |
7,477 |
74,821 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Global Commercial Ops. |
• • – |
2014-03-02 |
4 |
D |
$124.02 |
$934,739 |
D/D |
(7,537) |
90,865 |
0 |
- |
|
| BGNE |
Beigene Ltd |
Director |
– • – |
2021-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
7,800 |
7,800 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
President Americas |
• – – |
2009-12-23 |
4 |
S |
$0.00 |
$0 |
D/D |
(8,084) |
91,753 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Global Commercial Ops. |
• – – |
2012-04-27 |
4 |
A |
$0.00 |
$0 |
D/D |
8,654 |
67,227 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
President Americas |
• – – |
2010-03-06 |
4 |
OE |
$24.60 |
$214,438 |
D/D |
8,717 |
119,344 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
SVP ComOps Pres USJap Int |
• – – |
2011-03-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,717 |
169,390 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Global Commercial Ops. |
• • – |
2018-03-23 |
4 |
D |
$176.08 |
$1,550,737 |
D/D |
(8,807) |
211,522 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
SVPComOps PresUSJapInterc |
• – – |
2011-03-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,921 |
162,295 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
President US Pharmaceuticals |
• – – |
2005-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
9,306 |
71,520 |
|
- |
|
| BMY |
Bristol-Myers Squibb Co |
President US Pharmaceuticals |
• – – |
2004-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
10,556 |
62,801 |
|
- |
|
| BMY |
Bristol-Myers Squibb Co |
President Americas |
• – – |
2009-02-19 |
4/A |
D |
$20.51 |
$246,099 |
D/D |
(11,999) |
108,419 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Global Commercial Ops. |
• • – |
2017-03-24 |
4 |
D |
$166.04 |
$2,013,733 |
D/D |
(12,128) |
198,482 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
SVP ComOps Pres USJap Int |
• – – |
2011-05-13 |
4 |
S |
$28.80 |
$385,104 |
D/D |
(13,372) |
530,806 |
0 |
- |
|
| BGNE |
Beigene Ltd |
Director |
– • – |
2022-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
16,692 |
24,492 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
President Americas |
• – – |
2010-03-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(17,259) |
110,627 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Global Commercial Ops. |
• • – |
2018-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
17,638 |
220,121 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Global Commercial Ops. |
• • – |
2017-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
23,092 |
210,397 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Global Commercial Ops. |
• • – |
2016-03-25 |
4 |
D |
$149.24 |
$3,549,673 |
D/D |
(23,785) |
185,855 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
President US Pharmaceuticals |
• – – |
2006-03-07 |
4 |
A |
$22.73 |
$545,679 |
D/D |
24,007 |
117,458 |
|
- |
|
| BMY |
Bristol-Myers Squibb Co |
President US Pharmaceuticals |
• – – |
2005-09-20 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
93,451 |
|
- |
|
| BMY |
Bristol-Myers Squibb Co |
President US Pharmaceuticals |
• – – |
2009-02-19 |
4 |
A |
$0.00 |
$0 |
D/D |
25,830 |
120,418 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Global Commercial Ops. |
• • – |
2013-03-13 |
4 |
D |
$91.75 |
$2,526,795 |
D/D |
(27,540) |
93,060 |
0 |
- |
|
93 Records found
|
|
Page 3 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
